These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104 [TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176 [TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis. Zhou Y; Li A; Yu H; Wang Y; Zhang X; Qiu H; Du W; Luo L; Fu S; Zhang L; Hong S JAMA Netw Open; 2024 Mar; 7(3):e241285. PubMed ID: 38451524 [TBL] [Abstract][Full Text] [Related]
5. Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies. Nuccio A; Viscardi G; Salomone F; Servetto A; Venanzi FM; Riva ST; Oresti S; Ogliari FR; Viganò M; Bulotta A; Cameron R; Esposito A; Hines J; Bianco R; Reni M; Cascone T; Garassino MC; Torri V; Veronesi G; Cinquini M; Ferrara R Eur J Cancer; 2023 Dec; 195():113404. PubMed ID: 37948842 [TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
7. Is neoadjuvant immunotherapy necessary in patients with programmed death ligand 1 expression-negative resectable non-small cell lung cancer? A systematic review and meta-analysis. Zhang SL; Tian Y; Yu J; Zhang JH; Sun L; Huang LT; Ma JT; Han CB Lung Cancer; 2024 May; 191():107799. PubMed ID: 38669725 [TBL] [Abstract][Full Text] [Related]
8. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. Takahashi M; Cortés J; Dent R; Pusztai L; McArthur H; Kümmel S; Denkert C; Park YH; Im SA; Ahn JH; Mukai H; Huang CS; Chen SC; Kim MH; Jia L; Li XT; Tryfonidis K; Karantza V; Iwata H; Schmid P JAMA Netw Open; 2023 Nov; 6(11):e2342107. PubMed ID: 37966841 [TBL] [Abstract][Full Text] [Related]
10. The Value of Perioperative Immunotherapy for Non-Small Cell Lung Cancer: A Pool- and Meta-Analysis. Wu Y; Hu L; Zhang S; Zhang H Technol Cancer Res Treat; 2024; 23():15330338241258164. PubMed ID: 38872482 [No Abstract] [Full Text] [Related]
11. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials. Zhang W; Liang Z; Zhao Y; Li Y; Chen T; Li W; Chen Y; Wu P; Zhang H; Fang C; Li L Front Immunol; 2024; 15():1359302. PubMed ID: 38646542 [TBL] [Abstract][Full Text] [Related]
12. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis. Wang C; Qiao W; Jiang Y; Zhu M; Shao J; Wang T; Liu D; Li W J Cell Physiol; 2020 May; 235(5):4913-4927. PubMed ID: 31693178 [TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis. Xin Y; Shen G; Zheng Y; Guan Y; Huo X; Li J; Ren D; Zhao F; Liu Z; Li Z; Zhao J BMC Cancer; 2021 Nov; 21(1):1261. PubMed ID: 34814874 [TBL] [Abstract][Full Text] [Related]
14. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. Zhu J; Yuan Y; Wan X; Yin D; Li R; Chen W; Suo C; Song H Cochrane Database Syst Rev; 2021 Dec; 12(12):CD011300. PubMed ID: 34870327 [TBL] [Abstract][Full Text] [Related]
15. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer. Yang ZY; Liu L; Mao C; Wu XY; Huang YF; Hu XF; Tang JL Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD009948. PubMed ID: 25400254 [TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysis. Wu Y; Verma V; Gay CM; Chen Y; Liang F; Lin Q; Wang J; Zhang W; Hui Z; Zhao M; Wang J; Chang JY Cancer; 2023 Jul; 129(13):1969-1985. PubMed ID: 36994945 [TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer. Zhang X; Zhang H; Hou F; Fang T; Zhang C; Wang H; Song S; Lan H; Wang Y; Hou H World J Surg Oncol; 2024 Jun; 22(1):159. PubMed ID: 38890622 [TBL] [Abstract][Full Text] [Related]
18. Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Maiorano BA; Di Maio M; Cerbone L; Maiello E; Procopio G; Roviello G; JAMA Netw Open; 2024 Mar; 7(3):e241215. PubMed ID: 38446479 [TBL] [Abstract][Full Text] [Related]
19. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis. Li Y; Liang X; Li H; Chen X Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]